Serum proteomics in amnestic mild cognitive impairment

Proteomics

Volumn 13, Issue 16, 2013, Pages 2526-2533

  Ijsselstijn, Linda ^a   Papma, Janne M ^a   Dekker, Lennard J M ^a   Calame, Wim ^b   Stingl, Christoph ^a   Koudstaal, Peter J ^a   Prins, Niels D ^a,c   Sillevis Smitt, Peter A E ^a   Luider, Theo M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b StatistiCal BV   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Amnestic; Biomedicine; MCI; Serum

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; APOLIPOPROTEIN E; ARGININE CARBOXYPEPTIDASE; CARBOXYPEPTIDASE N SUBUNIT 2; GALECTIN 3 BINDING PROTEIN; LUMICAN; PROTEIN; SERUM AMYLOID A; SERUM AMYLOID A 4; SERUM AMYLOID P; SEX HORMONE BINDING GLOBULIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MILD COGNITIVE IMPAIRMENT; MRM ASSAY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROCEDURES; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; STUDENT T TEST;

EID: 84881483960     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201200190     Document Type: Article

References (38)

1. Burns, A., Zaudig, M., Mild cognitive impairment in older people. Lancet 2002, 360, 1963-1965.
2. Petersen, R. C., Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 2004, 256, 183-194.
3. Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C. et al., Current concepts in mild cognitive impairment. Arch. Neurol. 2001, 58, 1985-1992.
4. Ewers, M., Walsh, C., Trojanowski, J. Q., Shaw, L. M. et al., Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol. Aging 2010, 33, 1203-1214.e2.
5. Frank, R. A., Galasko, D., Hampel, H., Hardy, J. et al., Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol. Aging 2003, 24, 521-536.
6. Song, F., Poljak, A., Smythe, G. A., Sachdev, P., Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. Brain Res. Rev. 2009, 61, 69-80.
7. Blasko, I., Jellinger, K., Kemmler, G., Krampla, W. et al., Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol. Aging 2008, 29, 1-11.
8. Artero, S., Petersen, R., Touchon, J., Ritchie, K., Revised criteria for mild cognitive impairment: validation within a longitudinal population study. Dement. Geriatr. Cogn. Disord. 2006, 22, 465-470.
9. McKhann, G., Drachman, D., Folstein, M., Katzman, R. et al., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34, 939-944.
10. van den Herik, E. G., Cheung, E. Y., de Lau, L. M., den Hertog, H. M. et al., γ'/Total fibrinogen ratio is associated with short term outcome in ischaemic stroke. Thromb. Haemost. 2011, 105, 430-434.
11. IJsselstijn, L., Dekker, L. J., Koudstaal, P. J., Hofman, A. et al., Serum clusterin levels are not increased in presymptomatic Alzheimer's disease. J. Proteome Res. 2011, 10, 2006-2010.
12. MacLean, B., Tomazela, D. M., Shulman, N., Chambers, M. et al., Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 2010, 26, 966-968.
13. Cohen, J., Statistical Power Analysis for the Behavioral Sciences, Lawrence Erlbaum Associates, Mahwah, NJ 1988.
14. Afifi, A., Clark, V., May, S., Computer-Aided Multivariate Analysis Chapman & Hall, Boca Raton, FL 2004.
15. Kleinbaum, D. G., Kupper, L. L., Muller, K. E., Nizam, A., Applied Regression Analysis and Other Multivariable Methods, Duxbury Press, Pacific grove, CA 1998.
16. IJsselstijn, L., Dekker, L. J., Stingl, C., van der Weiden, M. M. et al., Serum levels of pregnancy zone protein are elevated in presymptomatic Alzheimer's disease. J. Proteome Res. 2011, 10, 4902-4910.
17. Ricklin, D., Hajishengallis, G., Yang, K., Lambris, J. D., Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11, 785-797.
18. Veerhuis, R., Nielsen, H. M., Tenner, A. J., Complement in the brain. Mol. Immunol. 2011, 48, 1592-1603.
19. Velazquez, P., Cribbs, D. H., Poulos, T. L., Tenner, A. J., Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis. Nat. Med. 1997, 3, 77-79.
20. Matthews, K. W., Mueller-Ortiz, S. L., Wetsel, R. A., Carboxypeptidase N: a pleiotropic regulator of inflammation. Mol. Immunol. 2004, 40, 785-793.
21. Farrall, A. J., Wardlaw, J. M., Blood-brain barrier: ageing and microvascular disease-systematic review and meta-analysis. Neurobiol. Aging 2009, 30, 337-352.
22. Breteler, M. M., Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann. N. Y. Acad. Sci. 2000, 903, 457-465.
23. Inohara, H., Akahani, S., Koths, K., Raz, A., Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res. 1996, 56, 4530-4534.
24. Ullrich, A., Sures, I., D'Egidio, M., Jallal, B. et al., The secreted tumor-associated antigen 90K is a potent immune stimulator. J. Biol. Chem. 1994, 269, 18401-18407.
25. Fukaya, Y., Shimada, H., Wang, L. C., Zandi, E., DeClerck, Y. A., Identification of galectin-3-binding protein as a factor secreted by tumor cells that stimulates interleukin-6 expression in the bone marrow stroma. J. Biol. Chem. 2008, 283, 18573-18581.
26. Kalayci, O., Birben, E., Tinari, N., Oguma, T. et al., Role of 90K protein in asthma and TH2-type cytokine expression. Ann. Allergy Asthma Immunol. 2004, 93, 485-492.
27. Grassadonia, A., Tinari, N., Iurisci, I., Piccolo, E. et al., 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj. J. 2004, 19, 551-556.
28. de Beer, M. C., Yuan, T., Kindy, M. S., Asztalos, B. F. et al., Characterization of constitutive human serum amyloid A protein (SAA4) as an apolipoprotein. J. Lipid Res. 1995, 36, 526-534.
29. Liang, J. S., Sloane, J. A., Wells, J. M., Abraham, C. R. et al., Evidence for local production of acute phase response apolipoprotein serum amyloid A in Alzheimer's disease brain. Neurosci. Lett. 1997, 225, 73-76.
30. Pepys, M. B., Dyck, R. F., de Beer, F. C., Skinner, M., Cohen, A. S., Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin. Exp. Immunol. 1979, 38, 284-293.
31. Picken, M. M., Amyloidosis-where are we now and where are we heading? Arch. Pathol. Lab. Med. 2010, 134, 545-551.
32. Tennent, G. A., Lovat, L. B., Pepys, M. B., Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 4299-4303.
33. Hawkins, P. N., Rossor, M. N., Gallimore, J. R., Miller, B. et al., Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease. Biochem. Biophys. Res. Commun. 1994, 201, 722-726.
34. Kimura, M., Asada, T., Uno, M., Machida, N. et al., Assessment of cerebrospinal fluid levels of serum amyloid P component in patients with Alzheimer's disease. Neurosci. Lett. 1999, 273, 137-139.
35. Mulder, C., Schoonenboom, S. N., Wahlund, L. O., Scheltens, P. et al., CSF markers related to pathogenetic mechanisms in Alzheimer's disease. J. Neural. Transm. 2002, 109, 1491-1498.
36. Nishiyama, E., Iwamoto, N., Kimura, M., Arai, H., Serum amyloid P component level in Alzheimer's disease. Dementia 1996, 7, 256-259.
37. Nybo, M., Olsen, H., Jeune, B., Andersen-Ranberg, K. et al., Increased plasma concentration of serum amyloid P component in centenarians with impaired cognitive performance. Dement. Geriatr. Cogn. Disord. 1998, 9, 126-129.
38. Verwey, N. A., Schuitemaker, A., van der Flier, W. M., Mulder, S. D. et al., Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2008, 26, 522-527.